Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders

IF 9.2 1区医学 Q1 IMMUNOLOGY

Autoimmunity reviews Pub Date : 2025-01-20 DOI:10.1016/j.autrev.2025.103754

Franz Felix Konen , Nora Möhn , Torsten Witte , Matthias Schefzyk , Miriam Wiestler , Svjetlana Lovric , Karsten Hufendiek , Konstantin Fritz Jendretzky , Stefan Gingele , Philipp Schwenkenbecher , Kurt-Wolfram Sühs , Manuel A. Friese , Luisa Klotz , Refik Pul , Marc Pawlitzki , David Hagin , Christoph Kleinschnitz , Sven G. Meuth , Thomas Skripuletz

{"title":"Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders","authors":"Franz Felix Konen , Nora Möhn , Torsten Witte , Matthias Schefzyk , Miriam Wiestler , Svjetlana Lovric , Karsten Hufendiek , Konstantin Fritz Jendretzky , Stefan Gingele , Philipp Schwenkenbecher , Kurt-Wolfram Sühs , Manuel A. Friese , Luisa Klotz , Refik Pul , Marc Pawlitzki , David Hagin , Christoph Kleinschnitz , Sven G. Meuth , Thomas Skripuletz","doi":"10.1016/j.autrev.2025.103754","DOIUrl":null,"url":null,"abstract":"<div><div>A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced. Those mechanisms of action include a broad therapeutic spectrum of substances targeting various protein kinases, some of which could also be used for the treatment of other autoimmune-mediated diseases. The advancement of new compounds could therefore enable a more personalized approach in treating MS, taking into consideration patients' co-existing autoimmune-mediated diseases. In this review, we discuss potential compounds targeting protein kinases, currently under investigation in clinical trials for various autoimmune diseases that could become viable treatment options for MS and comorbid autoimmune conditions in the future.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 4","pages":"Article 103754"},"PeriodicalIF":9.2000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmunity reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S156899722500014X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological processes underlying MS, the exploration of additional medical compounds within clinical trials has been ignited. Emerging novel medications with innovative mechanisms of action are being introduced. Those mechanisms of action include a broad therapeutic spectrum of substances targeting various protein kinases, some of which could also be used for the treatment of other autoimmune-mediated diseases. The advancement of new compounds could therefore enable a more personalized approach in treating MS, taking into consideration patients' co-existing autoimmune-mediated diseases. In this review, we discuss potential compounds targeting protein kinases, currently under investigation in clinical trials for various autoimmune diseases that could become viable treatment options for MS and comorbid autoimmune conditions in the future.

查看原文本刊更多论文

疾病改善策略：针对多发性硬化症和其他自身免疫性疾病的蛋白激酶

多种免疫调节疗法已经可用于多发性硬化症（MS）的治疗。通过基础研究的基本见解，在MS的病理过程中获得知识，在临床试验中探索额外的药物化合物已经被点燃。正在介绍具有创新作用机制的新兴新型药物。这些作用机制包括针对各种蛋白激酶的广泛治疗物质，其中一些也可用于治疗其他自身免疫介导的疾病。因此，考虑到患者共存的自身免疫介导性疾病，新化合物的进展可以使治疗MS的方法更加个性化。在这篇综述中，我们讨论了靶向蛋白激酶的潜在化合物，目前正在各种自身免疫性疾病的临床试验中进行研究，这些化合物将来可能成为多发性硬化症和合并症自身免疫性疾病的可行治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Autoimmunity reviews 医学-免疫学

CiteScore

24.70

自引率

4.40%

发文量

164

审稿时长

21 days

期刊介绍： Autoimmunity Reviews is a publication that features up-to-date, structured reviews on various topics in the field of autoimmunity. These reviews are written by renowned experts and include demonstrative illustrations and tables. Each article will have a clear "take-home" message for readers. The selection of articles is primarily done by the Editors-in-Chief, based on recommendations from the international Editorial Board. The topics covered in the articles span all areas of autoimmunology, aiming to bridge the gap between basic and clinical sciences. In terms of content, the contributions in basic sciences delve into the pathophysiology and mechanisms of autoimmune disorders, as well as genomics and proteomics. On the other hand, clinical contributions focus on diseases related to autoimmunity, novel therapies, and clinical associations. Autoimmunity Reviews is internationally recognized, and its articles are indexed and abstracted in prestigious databases such as PubMed/Medline, Science Citation Index Expanded, Biosciences Information Services, and Chemical Abstracts.